JPMorgan raised the firm’s price target on Mereo BioPharma (MREO) to $8 from $7 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO:
- Mereo Biopharma Group Plc: Strategic Advancements and Promising Developments Justify Buy Rating
- Promising Future for Mereo Biopharma: Buy Rating Backed by Positive Trial Prospects and Strong Market Position
- Mereo BioPharma Reports Increased Losses Amid Strategic Focus
- Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Strong Financial Position and Promising Study Results
- Mereo BioPharma reports Q2 EPS (2c), consensus (1c)